

Calcium Channel Blockers Treatment Selector

Charts revised December 2021. Full information available at www.hiv-druginteractions.org

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

	ATV/c	ATV/r	DRV/c	DRV/r	LPV/r	DOR	EFV	ETV	NVP	RPV oral	FTR	MVC	BIC/F/TAF	CAB oral	CAB/RPV	DTG	EVG/c/F/TAF	EVG/c/F/TDF	RAL	FTC/TAF	FTC/TDF	TDF
Calcium Channel Blockers																						
Amlodipine	↑♥	↑♥	↑	↑	↑♥	↔	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Diltiazem	↑♥	↑♥	↑	↑	↑♥	↑	↓69%	↓	↓	↑♥	↑♥	↑	↑ ^a	↔	↑♥	↔	↔	↔	↔	↔	↔	↔
Felodipine	↑♥	↑♥	↑	↑	↑♥	↔	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Lacidipine	↑♥	↑♥	↑	↑	↑♥	↔	↓	↓	↓	↔♥	↔♥	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Lercanidipine	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Nicardipine	↑♥	↑♥	↑	↑	↑♥	↑	↓	↓	↓	↑♥	↑♥	↑	↔	↔	↑♥	↔	↔	↔	↔	↔	↔	↔
Nifedipine	↑♥	↑♥	↑	↑	↑♥	↔	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Nisoldipine	↑♥	↑♥	↑	↑	↑♥	↔	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Verapamil	↑♥	↑♥	↑	↑	↑♥	↑	↓	↓	↓	↑	↑	↑	↑ ^b	↔	↑	↔	↑ ^c	↑ ^d	↔	↑ ^c	↑ ^d	↑ ^d

Interactions with CAB/RPV long acting injections
Pharmacokinetic interactions shown are mostly with RPV.
QT interactions shown are with RPV.

Interactions with Ibalizumab
None

Interactions with Abacavir (ABC), Lamivudine (3TC) or Zidovudine (ZDV)
ABC: No clinically relevant interactions expected.
3TC: No clinically relevant interactions expected.
ZDV: No clinically relevant interactions expected.

Colour Legend

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dose adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity. No *a priori* dosage adjustment is recommended.

Text Legend

- ↑ Potential increased exposure of the antihypertensive
 - ↓ Potential decreased exposure of the antihypertensive
 - ↔ No significant effect
 - ♥ One or both drugs may cause QT and/or PR prolongation. ECG monitoring is advised if coadministered with atazanavir or lopinavir. Rilpivirine and fostemsavir were shown to prolong the QT interval at supratherapeutic doses. Caution is advised with rilpivirine. ECG monitoring is advised with fostemsavir and drugs with a known QT prolongation risk.
- Numbers refer to increase or decrease in AUC as observed in drug-drug interaction studies.

Notes

- a** Coadministration may increase bicitegravir concentrations; no effect on emtricitabine or tenofovir alafenamide is expected.
- b** Coadministration may increase bicitegravir and tenofovir alafenamide concentrations; no effect on emtricitabine is expected.
- c** Coadministration could potentially increase the absorption of tenofovir alafenamide, thereby increasing the systemic concentration of tenofovir.
- d** Coadministration could potentially increase the absorption of tenofovir-DF, thereby increasing the systemic concentration of tenofovir. Monitoring of tenofovir-associated adverse reactions, including frequent renal monitoring, is recommended.